Optimal stroke preventive strategy for patients aged 80 years or older with atrial fibrillation: a systematic review with traditional and network meta-analysis.
Kun-Han LeeYing-Fan ChenWan-Yu YehJiunn-Tyng YehTzu-Han YangChian-Ying ChouYuh-Lih ChangWei-Ting WangChern-En ChiangChen-Huan ChenBabangida S ChoriPublished in: Age and ageing (2022)
In patients aged 80 years or older with AF, NOACs have better outcomes than VKAs regarding efficacy and safety profiles. Edoxaban and apixaban may be preferred treatment options since they are safer than other antithrombotic strategies.
Keyphrases
- atrial fibrillation
- end stage renal disease
- systematic review
- ejection fraction
- chronic kidney disease
- newly diagnosed
- heart failure
- prognostic factors
- peritoneal dialysis
- physical activity
- type diabetes
- randomized controlled trial
- metabolic syndrome
- catheter ablation
- left atrial appendage
- acute coronary syndrome
- coronary artery disease
- middle aged
- patient reported
- skeletal muscle
- mitral valve